Navigation Links
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Date:10/17/2007

Plans to Move Forward with Phase III

MALVERN, Pa., Oct. 17 /PRNewswire/ -- Cutanea Life Sciences, an emerging specialty pharmaceutical company focused on improving human health and appearance through the development and commercialization of treatments for diseased and aging skin conditions, today announced results from its completed Phase II clinical trial of Omiganan.

The trial compared Omiganan 2.5% and 1% topical gel to vehicle in subjects with papulopustular rosacea. Study results demonstrated that the formulation was safe and well-tolerated at all doses tested. Among the once-daily treatment arms, a dose-dependent response was observed in both lesion reductions and Treatment Success, as defined by Investigator Global Assessment (IGA) scores. After nine weeks of treatment, once-daily (QD) Omiganan 2.5% gel showed superior lesion count reductions and Treatment Success, compared to 1% Omiganan QD and vehicle. Omiganan provided greater improvements compared to vehicle among patients with a more severe condition at Baseline (more numerous inflammatory lesions). Lesion counts continued to drop at all evaluations over the duration of the study, indicating that further improvements may be expected with a duration of treatment exceeding nine weeks. Twice daily (BID) application of 2.5% Omiganan did not demonstrate substantial improvement in lesion reduction or the number of patients reaching Treatment Success compared to once daily application. Based on the results from this study, Cutanea has selected a once-daily dose of Omiganan 2.5% for further development for the treatment of papulopustular rosacea.

Dr. Guy Webster, Founding and Current President of the American Acne & Rosacea Society and Clinical Professor of Dermatology at Jefferson Medical College stated, "Topical Omiganan is a novel approach, actually the first in a new class of dermatologic drugs, for the treatment of rosacea. Initial results are promising and I look f
'/>"/>

SOURCE Cutanea Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... or "the Company"), a clinical stage biopharmaceutical company ... targeted therapeutics for the treatment of inflammatory diseases ... previously announced underwritten public offering of 3,450,000 units, ... the Company,s common stock, par value $0.0001 per ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... successful,KB2115 Phase II study meets primary objectives. The ... KB2115 in patients with dyslipidemia,has been successfully completed. ... respect to a broad range of parameters,reflecting effects ... thyroid hormone receptor (TR) is a key regulator ...
... the Congress of the European Hematology,Association, SAN ... , a biopharmaceutical company developing patient-specific,active immunotherapies ... from a Phase 2 clinical trial of ... (NHL). The data were,reported at the Congress ...
Cached Medicine Technology:Karo Bio Announces Sucessfule Phase II Results of KB2115 2Karo Bio Announces Sucessfule Phase II Results of KB2115 3Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe 2Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe 3
(Date:11/26/2014)... (PRWEB) November 26, 2014 The city ... water shortages, is moving forward with a plan to ... water.* Radio host Sharon Kleyne supports the San Diego ... Water Management” (TWM). According to Kleyne, by recycling water ... import new water could be greatly reduced. (Spagat, E, ...
(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... News Facts , Lexmark’s ... RSNA 2014 in Chicago. The company will demonstrate ... images, photos, videos and documents found throughout the ... learn more about these innovative medical content management ... initiatives – that enable more informed clinical decisions, ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Teens ... likely to abuse those drugs than other teens, ... the need to conduct substance abuse assessments on ... researchers said. "Prescribers and parents don,t realize ... a professor at the University of Michigan School ...
Breaking Medicine News(10 mins):Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... found a way to curb hunger, rev up energy ... of a brain enzyme may curb appetite and boost ... a new study. , Prolylcarboxypeptidase (PRCP) regulates the ... hunger while revving up the body,s energy levels. If ...
... , The National Comprehensive Cancer Network ... the Comparative Effectiveness of health care technologies in cancer care. This ... Effectiveness in Cancer Care to be held in December 2009 , ... The National Comprehensive Cancer Network (NCCN) ...
... , , , , ... Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL), ... innovation today announced a research and development collaboration agreement with nationally ... Research Institute LLC in Tamarac, FL. The partnership will allow Dr. ...
... , , RONKONKOMA, N.Y., July 22 NBTY, ... a leading global manufacturer and marketer of nutritional supplements, today announced ... the United Kingdom by the provisional findings of the Competition Commission. ... on or before September 3, 2009. , , ...
... , BOSTON, July 22 Don,t want a mediocre funeral ... Boston area options. , , "There are people ... even know they have a choice about how to proceed. You can educate ... to the fastest place they can, a funeral home. The funeral homes, though, ...
... ... announced today the formation of their Dentistry Council of Advisors (DCA). The DCA will include ... will help shape the direction of Dentra solutions to dental practices, labs, schools, manufacturers and ... satisfaction. , ...
Cached Medicine News:Health News:NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care 2Health News:NCCN Will Convene National Policy Summit on Comparative Effectiveness in Cancer Care 3Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 2Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 3Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 4Health News:Cryo-Cell Announces C'elle(SM) Research and Development Collaboration for Chronic Wound Healing Management 5Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 2Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 3Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 4Health News:NBTY Acquisition of Julian Graves Unconditionally Cleared 5Health News:The Boston Funeral Guide Is 'Live' 2Health News:Dentra™ Announces Dentistry Council of Advisors 2Health News:Dentra™ Announces Dentistry Council of Advisors 3
... providers can code the charge while completing a ... while away from office, both directly feeding the ... an Encounter Form/Superbill, data entry can be done ... patient payments are posted by reflecting open item ...
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... features 4 precisely angled 64° mirrors to ... anterior chamber angle with slight rotation. ... element) provides a stable platform during laser ... mirror lens provides a complete view of ...
Medicine Products: